Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in significant morbidity and mortality worldwide. Despite a successful vaccination programme, the emergence of mutated variants that can escape current levels of immunity mean infections continue. Herein...

Descripción completa

Detalles Bibliográficos
Autores principales: Seo, Ji-Min, Kang, Bobin, Song, Rina, Noh, Hanmi, Kim, Cheolmin, Kim, Jong-In, Kim, Minsoo, Ryu, Dong-Kyun, Lee, Min-Ho, Yang, Jeong-Sun, Kim, Kyung-Chang, Lee, Joo-Yeon, Lee, Hansaem, Woo, Hye-Min, Kim, Jun-Won, Choi, Jung-Ah, Song, Manki, Tomaszewska-Kiecana, Monika, Wołowik, Anna, Kulesza, Agnieszka, Kim, Sunghyun, Ahn, Keumyoung, Jung, Nahyun, Lee, Soo-Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Coronaviruses
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542283/
https://www.ncbi.nlm.nih.gov/pubmed/36006772
http://dx.doi.org/10.1080/22221751.2022.2117094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542283/
https://www.ncbi.nlm.nih.gov/pubmed/36006772
http://dx.doi.org/10.1080/22221751.2022.2117094

Ejemplares similares